/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
TechTarget Integrates 1st and 3rd Party Intent Data within Priority Engine Platform to Help Companies Make Faster Sales and Marketing Progress with Best Fit Accounts
Enhanced account prioritization and intelligence combines
relevant TechTarget intent, fit and customer engagement data to improve
sales and marketing conversions
NEWTON, Mass.–(BUSINESS WIRE)–TechTarget,
Inc. (Nasdaq: TTGT), the global leader in B2B technology purchase
intent data and services today announced the release of enhanced account
rankings and insights in IT Deal Alert Priority
EngineTM, fueled by 1st and 3rd
party purchase intent data. Marketing and sales teams will now be able
to leverage this new intelligence to get to the right accounts and
prospects faster, increasing conversions and accelerating pipeline.
“TechTarget has always focused on delivering ROI,” said Michael Cotoia,
CEO, TechTarget. “These new updates now make it even easier for our
customers to close deals faster by helping them find the prospects that
are directly in their sweet spot.”
TechTarget’s Priority Engine is a SaaS-based platform that delivers
direct access to the most active in-market accounts and fully
permissioned prospects doing purchase research in specific technology
markets. In addition to providing exclusive third-party intent insights
on the topical interests of accounts, recency and relevancy of activity,
vendor consideration and installed technologies, TechTarget is now able
to integrate multiple first-party insights, such as Ideal Customer
Profile (ICP) matching, direct engagement on a vendor’s website and
specific interactions buyers have with a customer’s content and
advertising across the TechTarget network within the platform to deliver
vastly improved account prioritization capabilities. This latest release
provides better tools for enterprise technology marketing and sales
teams to more effectively reach and engage high value accounts within
their total addressable market, including:
-
Personalized account rankings that reflect organic research
with TechTarget AND direct engagement with the customer to improve
marketing and sales effectiveness. -
Ideal Customer Profile creation and filtering directly within
Priority Engine to efficiently find, track and convert identified best
fit customers. -
Enhanced qualification intelligence showcases the key
attributes that make accounts high priority targets, including: buying
stage, ICP match and if there is a confirmed project. -
Improved engagement signals show you precisely when accounts
visit your website, click on your banners and/or download your content. -
Indicators of new and recent activities give sales users new
reasons to call and help them engage the buying team with highly
tailored outreach.
TechTarget, named a Leader in The Forrester WaveTM: B2B
Marketing Data Providers, Q3 2018, has cemented its leadership in its
space because of the significant value and ROI its customers achieve.
TechTarget purchase intent insight is uniquely powerful because of how
it is made and how it is delivered to B2B tech marketers and sales
professionals. The actionable insights within the Priority Engine
platform are achievable because of the depth of original
decision-support content spanning 10,000 unique IT topics across
TechTarget’s network of over 140 enterprise technology-specific websites
as well as the Company’s suite of marketing and sales engagement
services.
“Over the past six months we’ve been focused on bringing even more
actionable data into Priority Engine to help our customers more
efficiently identify and make progress with best fit accounts,” said
Andrew Briney, Senior Vice President of Products, TechTarget. “This
release marks a major milestone in these efforts and a big leap forward
for the platform.”
To learn more about Priority Engine, please or visit TechTarget.com/Priority-Engine.
About TechTarget
TechTarget
(Nasdaq: TTGT) is the global leader in purchase intent-driven marketing
and sales services that deliver business impact for enterprise
technology companies. By creating abundant, high-quality editorial
content across more than 140 highly targeted technology-specific
websites, TechTarget attracts and nurtures communities of technology
buyers researching their companies’ information technology needs. By
understanding these buyers’ content consumption behaviors, TechTarget
creates the purchase intent insights that fuel efficient and effective
marketing and sales activities for clients around the world.
TechTarget has offices in Boston, London, Munich, Paris, San Francisco,
Singapore and Sydney. For more information, visit techtarget.com
and follow us on Twitter @TechTarget.
(C) 2019 TechTarget, Inc. All rights reserved. TechTarget and the
TechTarget logo are registered trademarks and IT Deal Alert and Priority
Engine are trademarks of TechTarget. All other trademarks are the
property of their respective owners.
Contacts
Media Inquiries
Garrett Mann
Director of Marketing
TechTarget,
Inc.
617-431-9371
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
transfer
IMC to transfer its Oranim Pharmacy shares back to the seller
TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the seller.
“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, the occurrence of growth opportunities and the likelihood of growth potential.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East
Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.
The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contacts:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]
Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html
Cannabis
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Avant2 weeks ago
Avant and IMC Execute BLK MKT™ Trademark Licensing Agreement for the German Medical Cannabis Market
-
StickIt2 weeks ago
StickIt Technologies Inc. Announces Year-End 2023 Financial Results
-
Cannabis1 week ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis1 week ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis1 week ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis1 week ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis1 week ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
Cannabis1 week ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services